The Lancet, Early Online Publication, 1 July 2009
doi:10.1016/S0140-6736(09)60949-1Cite or Link Using DOI

Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial

Original Text
Patricia Jabre MD a b c, Xavier Combes MD b, Frederic Lapostolle MD a, Mohamed Dhaouadi MD d, Agnes Ricard-Hibon MD e, Benoit Vivien MD f, Lionel Bertrand MD g, Alexandra Beltramini MD h, Pascale Gamand MD i, Stephane Albizzati MD j, Deborah Perdrizet MD k, Gaelle Lebail MD l, Charlotte Chollet-Xemard MD b, Virginie Maxime MD m, Prof Christian Brun-Buisson MD n, Prof Jean-Yves Lefrant MD o, Prof Pierre-Edouard Bollaert MD j, Prof Bruno Megarbane MD p, Prof Jean-Damien Ricard MD q, Nadia Anguel MD r, Prof Eric Vicaut MD s, Prof Frederic Adnet MD a , on behalf of the KETASED Collaborative Study Group


Critically ill patients often require emergency intubation. The use of etomidate as the sedative agent in this context has been challenged because it might cause a reversible adrenal insufficiency, potentially associated with increased in-hospital morbidity. We compared early and 28-day morbidity after a single dose of etomidate or ketamine used for emergency endotracheal intubation of critically ill patients.


In this randomised, controlled, single-blind trial, 655 patients who needed sedation for emergency intubation were prospectively enrolled from 12 emergency medical services or emergency departments and 65 intensive care units in France. Patients were randomly assigned by a computerised random-number generator list to receive 0·3 mg/kg of etomidate (n=328) or 2 mg/kg of ketamine (n=327) for intubation. Only the emergency physician enrolling patients was aware of group assignment. The primary endpoint was the maximum score of the sequential organ failure assessment during the first 3 days in the intensive care unit. We excluded from the analysis patients who died before reaching the hospital or those discharged from the intensive care unit before 3 days (modified intention to treat). This trial is registered with, number NCT00440102.


234 patients were analysed in the etomidate group and 235 in the ketamine group. The mean maximum SOFA score between the two groups did not differ significantly (10·3 [SD 3·7] for etomidate vs 9·6 [3·9] for ketamine; mean difference 0·7 [95% CI 0·0—1·4], p=0·056). Intubation conditions did not differ significantly between the two groups (median intubation difficulty score 1 [IQR 0—3] in both groups; p=0·70). The percentage of patients with adrenal insufficiency was significantly higher in the etomidate group than in the ketamine group (OR 6·7, 3·5—12·7). We recorded no serious adverse events with either study drug.


Our results show that ketamine is a safe and valuable alternative to etomidate for endotracheal intubation in critically ill patients, and should be considered in those with sepsis.


French Ministry of Health.